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Summary
The importance of the Rho-GTPases in cancer progression, particularly in the area of metastasis, is becoming
increasingly evident. This review will provide an overview of the role of the Rho-regulatory proteins in breast
cancer metastatis.
Introduction
The formation and growth of metastases at a distant
site is the principal cause of death for most can-
cer patients, particularly those with breast cancer [1].
Metastases from the breast commonly occur in the
sentinal and axillary lymph nodes, the controlateral
breast, lungs, spinal cord, brain and bones [2]. Iron-
ically, it has been suggested that less than 0.1% of
neoplastic cells in a primary tumor have the ability
to successfully form metastases at distant sites [1].
The inability of the majority of tumor cells to success-
fully form metastases results from single or multiple
phenotypic deficiencies [3–5].
In order for a tumor cell to successfully metas-
tasize it must perform an ordered series of steps
that constitute the metastatic cascade. The tumor cell
must invade the tissue surrounding the primary tu-
mor, extravasate to the lymphatics or directly to the
blood supply, avoid host immune defenses, arrest at
the distant site, intravasate and grow [1]. Two key
components in obtaining metastatic competence are
the acquisition of a motile and invasive phenotype.
A historical perspective of the Rho-GTPases
Many of the diverse components of the meta-
static phenotype are controlled by members of the
Ras-superfamily of small GTP-binding proteins. The
Ras-superfamily currently boasts in excess of 130
members, which fall into the Ras, Rho, Arf/Sar1 and
Rab/Ran-subfamilies (reviewed in [6]).
All aspects of cellular motility and invasion, in-
cluding cellular polarity, cytoskeletal organization,
and transduction of signals from the outside environ-
ment are controlled through an interplay between the
Rho-GTPases [7–17]. The Rho-GTPases subfamily
consists of small, 20–30 kDa monomeric GTP-binding
proteins that are highly conserved throughout evolu-
tion in a variety of organisms [18]. Like Ras, Rho pro-
teins are able to bind GDP/GTP and hydrolyze GTP
leading to activation of downstream effector molecules
subsequently leading to a cellular response [18, 19].
While in their GDP-bound state the GTPases are in-
active; conversely when GTP-bound they are active
[18–20].
Rho was first isolated in 1985 due to its homol-
ogy to Ras (Rho stands for Ras homologous) from the
sea slug, Aplysia Californica [18]. Identification of
three closely related human Rho homologues, RhoA,
RhoB and RhoC, soon followed [18]. Other members
of the Rho-subfamily were later identified in the early
1990’s. Human Cdc42 (a homologue of yeast Cdc42),
Rac1 and Rac2 were found to be distinct in function
from the other Rho proteins [20–23].
In the time since A. Californica Rho was first de-
scribed, at least 21 Rho-family genes encoding at
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Figure 1. The Rho GTPase subfamily organized by their structure,
biochemical features and function. Even though some of these pro-
teins are highly homologous to one another (i.e., RhoA, RhoB and
RhoC), they are distinct in their cellular function and consequently
the phenotype they produce in cells. This family tree is based on
reviews by Wherlock et al. [17] and Ridley [24].
least 23 signaling molecules have been identified in
humans [17]. These proteins, although related, are dis-
tinct from one another and are organized on the Rho
‘family-tree’ by virtue of their structural, biochem-
ical and functional features (Figure 1) (reviewed in
[17, 24]). Similar to Ras, Rho proteins are localized
to the inner plasma membrane by a C-terminal lipid
modification. Localization to the plasma membrane is
necessary for activation [25]. Interestingly, some Rho-
family members such as Rnd and RhoH appear to lack
intrinsic GTPase activity [26–28].
Out of the nearly two dozen Rho genes that have
been identified, four members of the Rho-family,
RhoA, RhoB, Rac1 and Cdc42, have been studied
extensively. A series of elegant experiments were per-
formed early on to determine the functions of the
RhoA, Rac1 and Cdc42 proteins. At nearly the same
time that RhoA was identified, C3 exotransferase, a
toxin derived from Clostridium botulinum was found
to effectively target Rho (A, B and C) proteins (and
later found to have little or no effect on Rac1 or Cdc42)
[29–32]. C3 exotransferase inhibits Rho protein activ-
ity by promoting ADP-ribosylation of asparagine 41
and thereby inhibiting the interaction between GTP-
bound Rho and downstream effector molecules [30].
Although the active state of Rho is unaffected, the GT-
Pase is rendered ineffectual. Using a combination of
C3 exotransferase treatment and transfection of cells
with constituatively-active forms of RhoA, the Hall
and Ridley groups demonstrated the role of Rho in
organizing the actin cytoskeleton, specifically forming
bundles of actin stress fibers [19, 33]. Other experi-
ments utilizing dominant-negative forms of Rac1 and
Cdc42 established those proteins role in forming actin-
rich lamellipodia and filopodia, respectively [20–22].
Thus, the individual role of each of these GTPases in
cellular motility was established. Rac1 forms the lead-
ing lamellipodial edge of the cell. Cdc42 forms the
‘ruffles’ or ‘microspikes’ known as filopodia, which
redistribute the cell membrane to lamellipodium ex-
tension as the cell migrates. And RhoA redistributes
the actin stress fibers contracting the cell body in the
direction of cell movement. Additional roles of Rho
proteins have been demonstrated including control of
vesicular trafficking, apoptosis, cellular transforma-
tion, cell adhesion, angiogenesis and growth control
apoptosis [34–42].
A great deal of excitement ensued over the discov-
ery of Rho-GTPases, as many investigators assumed
that due to their homology to Ras, the Rho proteins
would also be oncogenes in human cancer. The three
isoforms of Ras, Ha-Ras, Ki-Ras and N-Ras, were
identified early in the 1980’s as oncogenes mutated in
a variety of human cancers [43–48].
Approximately, 30% of human tumors carry an
identifiable Ras mutation, which render the GTPase
incapable of hydrolyzing bound GTP, thus remaining
constitutively active [49]. Breast cancer is the excep-
tion, where approximately 5% of tumors harbor an
activating Ras mutation [50]. However, in contrast to
Ras, no mutation in any of the Rho proteins has been
identified in human tumors. Rather, overexpression of
Rho proteins, particularly RhoA and RhoC, appears to
be the rule in human cancers [8, 10, 51–57].
RhoA and RhoC GTPase overexpression
in breast cancer
Initial experiments demonstrated that activated A.
Californica Rho and RhoA GTPase could act as a
dominant oncogene and induce cellular transforma-
tion [33, 58, 59]. RhoB GTPase was also shown
to play a role in Ras-induced transformation [60].
This promoted several investigators to search several
types of human cancers for RhoA mutations. Moscow
et al. surveyed breast, ovarian, renal, lung and colon
carcinomas specimens for RhoA gene mutations and
performed chromosomal analysis on 3p21, the lo-
cation of the RhoA gene and an area known to be
deleted in several of these cancers [52]. No muta-
tions in RhoA were found, nor was there a correlation
between RhoA mRNA expression and the presence or
absence of 3p21 deletions. This finding has recently
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been validated by Rihet et al. who compared 14
invasive breast carcinomas with corresponding lymph
node metastases [61]. Using RT-PCR followed by
denaturing gradient gel electrophoresis (DGGE) to de-
tect the presence of heteroduplexes, the group did not
find any RhoA mutations in the patient samples.
Fritz et al. compared tissue from breast, lung and
colon with corresponding normal tissue originating
from the same patient for RhoA, Rac1 and Cdc42 ex-
pression [51]. RhoA protein levels were significantly
increased in the all three tumor types as compared with
the corresponding normal tissue. Of particular note,
protein levels of RhoA, Rac1 and Cdc42 were barely
detectable in normal mammary tissue, but were highly
expressed in all of the breast tumors tested. Interest-
ingly, they found that RhoA protein levels correlated
with increasing breast tumor grade. These findings
suggest that overexpression of Rho GTPases, partic-
ularly overexpression of RhoA, is a frequent and early
event in human cancers.
The role of Rho proteins in breast cancer meta-
stasis has recently been explored. A panel of MTLn3
rat mammary carcinoma cell lines expressing domi-
nant negative mutants of RhoA, Rac1, or Cdc42 was
implanted into nude mice [62]. Individually, each
dominant negative Rho protein reduced intravasation
into the bloodstream and subsequent metastasis [62].
Similarly, it was found that the Ras-Erk and RhoA-
Rho kinase (ROCK) pathways cooperate in uorkinase-
type plasminogen activator stimulated MCF7 breast
cancer cell migration [63]. Both of these studies
suggest that the Rho-ROCK, Rac1 and Cdc42 path-
ways are required for breast cell migration and meta-
stasis.
Inflammatory breast cancer (IBC) is a phenotypi-
cally distinct form of locally breast cancer that is
highly invasive to the dermal lymphatics and as a con-
sequence is highly metastatic [2, 64–67]. In an attempt
to identify genes involved in the unique IBC pheno-
type, Merajver’s laboratory identified RhoC GTPase
as being overexpressed in the SUM149 IBC cell line
using differential display [54]. In a blinded compar-
ison of IBC samples with stage-matched, non-IBC
breast tumor specimens, RhoC was found to be over-
expressed in more than 90% of IBC tumors compared
with 38% of the non-IBC samples [54]. Subsequently,
RhoC overexpression has been found to be a po-
tential prognostic marker for small breast tumors
(≤1 cm) with a propensity to metastasize [68]. Sim-
ilar to RhoA, the mechanism of RhoC overexpression
in breast cancer is unknown. Southern blot analysis
comparing normal human mammary epithelial (HME)
cells and the SUM102 breast cancer cell line (which
does not overexpress RhoC) with the SUM149 and
SUM190 IBC cell lines, did not reveal abnormal
gene amplifications or rearrangements (van Golen and
Merajver, unpublished observations).
Forced expression of wild-type RhoC in immortal-
ized HME cells nearly recapitulates the IBC pheno-
type [53, 69]. RhoC overexpressing HME cells grow
in soft agar, produce active angiogenic factors, are
highly motile, invasive and form orthotopic tumors
and micrometastases in nude mice. Treatment of the
HME-RhoC cells with C3 exotransferase inhibits the
RhoC induced phenotype [14]. Through the use of
pharmacologic inhibitors on the SUM149 IBC and
HME-RhoC cells, it was determined that RhoC GT-
Pase signals through the phosphoinositide-3-kinase
(PI3-K) and mitogen activated protein kinase (MAPK)
pathways [14]. Specifically, the ability to grow un-
der anchorage-independent conditions signals through
the PI3-K pathway, while motility and invasion sig-
nal through the Erk, JNK/SAPK, and p38 arms of
the MAPK pathway, and the production of angiogenic
factors signals through p38. As yet, the specific down-
stream Rho-effector molecules involved in RhoC sig-
naling are unknown. Although Rho-kinase (ROCK)
has been suggested to be a downstream target for
both RhoA and RhoC, treatment of the cells with the
pharmacologic ROCK inhibitor, Y-27632, does not
affect the RhoC-induced phenotype (van Golen and
Merajver, unpublished observations).
Figure 2. Example of a RhoC GTPase activation assay. GST-fusion
proteins of either the C21 Rhotekin Rho-binding domain or the PAK
CRIB domain are combine with cell lysates of untransfected HME,
β-galactosidase control transfected HME, RhoC transfected HME
and SUM149 IBC cells. The RhoC GST-fusion protein complex is
separated by SDS-PAGE, transferred to nitrocellulose and probed
with an anti-RhoC antibody. Active, GTP-bound RhoC was detected
in HME-RhoC and SUM149 cells in the GST-C21 pulldowns. No
active RhoC was detected in the GST-PAK pulldown assay because
the CRIB domain is specific for Rac1 and Cdc42. Dr John Collard of
the Netherlands Cancer Institute provided the reagents and protocol
for this assay.
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Another critical question that our laboratory is be-
ginning to address is the mechanism of RhoC GTPase
activation. Using a Rho-activation assay originated
and supplied by Dr John Collard [9, 70], and a RhoC
specific antibody generated in Merajver’s lab [68],
we have demonstrated that overexpressed, wild-type
RhoC is GTP-bound and active in the SUM149 and
HME-RhoC cell lines (Figure 2) [71]. We believe
that dysregulation of the Rho-regulatory proteins in-
volved in the normal control of the GTPase cycle
leads to aberrant RhoC activation in the absence of
mutation.
The GTPase cycle-A brief overview
Regulation of Ras and Rho GTPase activity is
achieved through the interactions of GTPase-activating
proteins (GAPs), GDP-dissociation inhibitors (GDIs),
GDI dissociation factors (GDFs), and guanine nucle-
otide exchange factors (GEFs) (Figure 3) [7, 72–74].
In order for Ras and Rho to enter into the GTPase
cycle, they must be localized to the inner cell mem-
brane via prenylation [73]. The entire cycle is balanced
by GDIs, which prevent GDP dissociation (leading to
GTP association) by binding to the prenylation group
of the GTPase and sequestering it in the cytoplasm
[75–78]. The GDP-bound GTPase is subsequently lib-
erated from the GDI by GDFs and localized to the
Figure 3. Overview of the GTPase cycle. Rxx-GTPase
= Rho-GTPase, Rac-GTPase or Ras-GTPase. (1) Stimulation
of a protein tyrosine kinase receptor stimulates (2) phosphorylation,
possible dimerization and transient inactivation of GAPs and (3)
activation of the GEFs. The GEFs catalyze the exchange of GDP
for GTP, activating the GTPase. (4) The active GTPase interacts
with downstream effector molecules resulting in (5) a cellular
response, in this example motility. (6) The GAP proteins catalyze
the hydrolysis of GTP to GDP leading to inactivation of the
GTPase. (7) The entire cycle is balanced by the GDIs, which binds
to the prenylation group of the GTPase keeping it sequestered and
inactive in the cytoplasm until released by GDFs.
inner plasma membrane [75]. While in the GDP-
bound state the GTPase is inactive. Activation of the
GEFs, typically by tyrosine kinase growth factor re-
ceptors, leads to exchange of the GDP for GTP, thus
activating the GTPase (reviewed in [79]). Binding of
GTP produces a conformational change in the GT-
Pase allowing interaction with downstream effector
proteins [72, 79–81]. Hydrolysis of GTP to GDP by
the intrinsic GTPase action activates the effector pro-
tein that leads to downstream signals and a cellular
response [72]. The interaction between Rho (A–C)
GTPase and downstream effectors is functionally in-
hibited by C3 exotransferase, which ADP-ribosylates
asparagine 41 of the GTPase [30]. Activation of GAPs
catalyzes hydrolysis of GTP to GDP, thus inactivating
the GTPase and terminating the interaction with down-
stream effector proteins, thereby closing the cycle [72,
82, 83].
The potential role of Rho-regulatory
proteins in breast cancer cell motility
Rho GDP dissociation inhibitors (RhoGDIs)
Like Ras, the Rho GTPases are post-translationally
modified to locate them to their distinct cell com-
partment so they can carry out their specific function
[25, 84, 85]. Each Rho protein contains a C-terminal
CAAX domain that determines prenylation and poly-
basic residues in the hypervariable domain, upstream
of the CAAX domain, which dictate proper membrane
localization [85].
Localization and trafficking of the Rho GTPases to
the cell membrane is a complex phenomenon. GDP-
bound Rho is prenylated and bound at the prenylation
site by specific RhoGDIs until liberated by RhoGDF,
transported to its specific membrane location and ac-
tivated by RhoGEF [75–78]. The type of prenylation
is Rho protein dependent. RhoA and RhoC GTPase
are geranylgeranylated, while RhoB can either be
geranylgeranylated or farnesylated [42, 85].
Many investigators working on the GDIs believe
that these proteins function to inhibit Rho activity
by ‘isolating’ Rho proteins at two distinct points,
(1) by directly preventing the exchange of GDP for
GTP by the GEFs and (2) by preventing intrinsic
and RhoGAP mediated GTP hydrolysis [86]. Several
lines of investigation support this idea. Microinjection
of RhoGDI into immortalized fibroblasts can signifi-
cantly inhibit their motility [87]. Similar results are
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achieved when RhoGDIs are overexpressed in hu-
man keratinocytes, leading to disruption of the actin
cytoskeleton and inhibition of motility [88].
Thus, since they function to inhibit Rho activity
and subsequently cellular motility, the RhoGDIs are
attractive candidates for regulating the activity of Rho
proteins in breast cancer cells. RhoGDIα overexpres-
sion has been shown to increase ERα, ERβ, androgen
and glucocorticoid receptor transcriptional activation
in mammalian cells [89]. Conversely, expression of
activated RhoA, Rac1 or Cdc42 lead to repression of
ER transcriptional levels [89]. Expression and activa-
tion of ERα and ERβ directly inhibits MDA-MB-231
breast cancer cell motility and invasion [90]. These
data therefore suggest that RhoGDIs can enhance ER
transcription and breast cancer cell motility through
inhibition of Rho activity.
Prendergast et al. have demonstrated that geranyl-
geranylated RhoB has tumor suppressor effects on
cancer cells [91–95]. Treatment of tumor cells with a
farnesyl transferase inhibitor (FTI) leads to a decrease
in farnesylated RhoB levels and a corresponding in-
crease in geranylgeranylated RhoB levels [91–95].
This effect is extended to RhoC overexpressing cells
[71]. FTI treatment of RhoC overexpressing HME or
SUM149 IBC cells leads to a marked decrease in their
motility and invasiveness. Presumably, FTI treatment
allows more geranylgeranylated RhoB to be available
for localization to the cell membrane, leaving GDI-
bound RhoC sequestered in the cytoplasm remaining
unavailable to the GEFs and GAPs.
Rho guanine exchange factors (RhoGEFs)
Because of their ability to catalyze the exchange of
GDP for GTP, coupled with their susceptibility to ac-
quire activating mutations, the RhoGEFs are probably
the best candidates for aberrant GTPase activation in
human cancer [79, 96]. The first RhoGEF to be iden-
tified in human cancer was the Dbl proto-oncogene.
Dbl was isolated during an attempt to clone unique
transforming factors from human B-cell lymphomas
and was found to be homologous to Cdc24, a Cdc42
specific RhoGEF found in yeast [96, 97]. Analysis of
Dbl demonstrated that mutations within the RhoGEF
could lead to constitutive activation of the GEF and
cellular transformation [97].
Since the discovery of Dbl, many Ras and
RhoGEFS have been identified due to their transform-
ing abilities. This growing family of proto-oncogenes
is identified by their structural similarity. The Dbl-like
RhoGEFs have an autoinhibitory domain to prevent
GDP/GTP exchange from occurring aberrantly [98,
99]. Upon phosphorylation and activation by pro-
tein tyrosine kinases or tyrosine kinase receptors, the
autoinhibitory domain is released and the RhoGEF is
activated. In the case of oncogenic RhoGEFs, such as
the Vav proto-oncogene, an activating mutation results
in deletion of the phosphorylation site and destruction
of the autoinhibitory mechanism [99].
All GEFs contain a conserved ∼150 amino acid
Dbl-homology (DH) domain immediately followed
by an ∼100 amino acid pleckstrin-homology (PH)
domain (reviewed in [100, 101]). Since the first de-
scriptions of Cdc24 in yeast and Dbl in humans, a very
large family of potential Ras- and RhoGEF proteins
has been identified over the years, all of which contain
the DH-PH domain and therefore comprise the largest
known family of proto-oncogenes.
It is the DH-PH domains that allow the GEFs to
interact with other molecules such as the Ras- and
Rho-GTPases and effect diverse cellular functions.
The PH domain binds to phosphoinositides, possibly
targeting the GEF to its cellular location [102]. The
PH domain also may regulate interactions with other
molecules and is essential in cellular transformation
by oncogenic GEF molecules [103–105]. It is the DH
domain that dictates the specificity of the RhoGEF
for single or multiple Rho proteins and allows the
GEF to interact with molecules other than the GTPases
that affect the arrangement of the actin cytoskeleton
[100]. A classic example is Trio, a Rac1- and RhoG-
GEF, which can induce membrane ruffling in cells
by directly interacting with filamin, an actin filament
crosslinking protein [103].
In addition to their interaction with GTPases and
actin-associated molecules, the GEFs can interact with
and be activated by several intrinsic kinases and pro-
tein tyrosine kinase growth factor receptors [79, 104,
106–109]. Several GEFs catalyze the exchange of
GDP for GTP in response to stimulation from growth
factors such as epidermal growth factor (EGF). Again,
the Vav family of RhoGEFs is an example of a group
of GEFs that are activated in response to growth factor
stimulation, particularly from the epidermal growth
factor receptor (EGFR) [110–113]. Coupled with the
fact that EGFR is typically overexpressed in IBC, the
Vav proteins make attractive candidates for the activa-
tion of RhoC in IBC cells [64]. This group of GEFs
consists of three family members, which can inter-
act with RhoA, Rac1 and Cdc42 [112–114]. Vav1
is found primarily in hematopoietic cells, but may
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be involved in human breast cancer, while Vav2 and
Vav3 are expressed ubiquitously in tissues [112–114].
Protein tyrosine kinase receptors, such as EGFR can
stimulate each of the Vav protein members leading
to Rho-GTPase activation, cytoskeletal reorganization
and cellular motility [110–113]. Although their in-
teraction with RhoC has not been explored, the Vav
family of RhoGEFs is an exciting potential control
point for regulating the diverse actions of the RhoC
phenotype in breast cancer.
Rho GTPase activating proteins (RhoGAPs)
As outlined above, intrinsic kinases and growth factors
receptors participate in the modulation of the GTPase
cycle by activating the GEFs, but they also effect
GAP activity. Ras and Rho GTPases can inactivate
themselves through an intrinsic GTPase activity that
hydrolyzes GTP to GDP. The kinetics of this reaction
is greatly increased by GAP proteins [83, 115, 116].
For example, hydrolysis of RhoA-GTP to RhoA-GDP
catalyzed by p190 RhoGAP is increased by 4000-fold
over RhoA-self mediated conversion [117].
The p190 protein is probably the best studied and
described of the RhoGAPs. p190 was first identi-
fied as a phosphorylated protein associated with p120
RasGAP in v-Src-transformed, growth factor stimu-
lated cells [118]. Two isoforms of p190 exist, the
more commonly studied p190-B and the putative tu-
mor suppressor gene, p190-A [119, 120]. Comparing
the GAP-domains of several putative RhoGAP pro-
teins, Ridley et al. demonstrated that p190 was a
Rho-specific GAP that induced actin cytoskeletal reor-
ganization [115]. p190 was found to have three distinct
functional domains; a N-terminal GTPase domain that
binds GDP/GTP in a similar fashion to Ras and Rho,
a middle domain (MD), which upon tyrosine phos-
phorylation is responsible for binding to a SH3 (Src
homology 3) domain flanked by two SH2 domains
on p120 RasGAP and a C-terminal GAP domain re-
sponsible for inactivation of GTP-bound Rho [115,
121–124].
Functional experiments demonstrated that inhibi-
tion of p190 leads to actin cytoskeletal reorganization
in 3T3 cells [125]. Treatment of cultured fibroblasts
with sodium fluoride (NaF) promoted the formation
of a high affinity complex between the Rho GTPases
and p190 RhoGAP. This effectively sequesters p190,
which is found in limiting concentrations in the cell,
and results in Rho activation. Furthermore, it was
demonstrated that treatment with low dose NaF and
lysophosphatidic acid (LPA), inhibited GAP activity
while stimulating GEF activity, further increasing Rho
activation. These findings suggests that inactivation of
Rho by p190 is essential for impeding constitutive Rho
activity and that the Rho GTPases are regulated by
a fine balance between inactivation by the GAPs and
activation by the GEFs.
Because p190 was first identified in Src trans-
formed cells, Fincham et al. addressed the role of
p190 in v-Src-mediated cytoskeletal reorganization of
chicken embryo fibroblasts [126]. They found that
activation of a temperature-dependent v-Src kinase
induced tyrosine phosphorylation of p190 RhoGAP
leading to association p120 RasGAP [126]. Switch-
ing off v-Src led to the dissociation of the p190/p120
heterodimer and the reformation of actin stress fibers
common to non-motile cells. Introduction of a con-
stitutively active RhoA mutant (Val14-RhoA), in the
presence of activated v-Src, also led to reformation of
actin stress fibers.
Many sites within all three domains of p190
RhoGAP can be phosphorylated and it is speculated
that kinases, such as c-Src and v-Src, and growth
factors utilize multiple sites to modulate a variety
of GAP activities. In vitro phosphorylation of the
N-terminal domain of p190 by c-Src, resulted in a
marked decrease in the ability of the GAP to directly
bind GTP [106]. While phosphorylation of tyrosine
residue 1105 in the MD was identified as the main
site for c-Src mediated p190/p120 heterodimer form-
ation [127]. These observations were furthered by
Haskell et al. who demonstrated that the MD and GAP
domains of p190 specifically regulate heterodimer for-
mation and Rho activity and actin reorganization in
response to c-Src transformation and EGF stimulation
[128].
Roof et al. demonstrated that EGF induced phos-
phorylation of tyrosine 1105 of p190 RhoGAP was re-
quired for heterodimer formation with p120 RasGAP
leading to a loss in GTP-binding, decreased GTP hy-
drolysis and actin reorganization [127]. At the time
of EGF activation, the p190 and p120 are located at
the inner plasma membrane [129]. Upon heterodimer
formation, the p190/p120 complex becomes associ-
ated with EGFR in an endocytic compartment and is
internalized [129].
The role of p190 RhoGAP in cell motility was in-
vestigated using fibroblasts isolated from p120 null
mouse embryos that lack the ability to polarize and
move in a wound assay [130]. Reintroduction of
wild-type p120 into the cells restored their ability to
Rho-regulatory proteins in breast cancer cell 55
polarize and undergo directional motility in a
p190/120 heterodimer dependent manner. Microinjec-
tion of the p190 MD domain into the motile cells
disrupted heterodimer formation leading to inhibition
of polarity and motility. Similarly, cellular aggreg-
ation occurs during engagement of E-cadherin and
phosphorylation of p120, presumably on a unique tyr-
osine residue, without p190 heterodimer formation
[131].
The vast majority of data detailing the function of
p190 RhoGAP in cellular motility has come from stud-
ies in fibroblasts. However, recent data suggests that
the p190/p120 heterodimer may play a role in breast
cancer motility and metastasis. Zhrihan-Licht et al.
demonstrated that stimulation of human breast cancer
cell lines by heregulin leads to the formation of multi-
protein complex and phosphorylation of RAFTK, a fo-
cal adhesion-related kinase [132]. Upon analysis they
determined that the complex consisted of RAFTK,
Her2/Neu, p190 RhoGAP, and p120 RasGAP. They
also demonstrated that RAFTK, which contains an in-
ternal Src binding domain, was found to mediate Src
phosphorylation of p190, and increase breast cancer
cell invasion.
GAPs in IBC cells
A plausible hypothesis on the role of p190 RhoGAP
and p120 RasGAP in RhoC-mediated IBC cell
motility can be formulated from the observations
presented above. EGFR amplification or Her2/Neu
expression leads to tyrosine phosphorylation and ac-
tivation of p190 RhoGAP and or p120 RasGAP.
In turn, p190 associates with p120 RasGAP form-
ing a heterodimer, which colocalizes in endocytic
membrane compartments with the activated EGFR or
Her2/neu. This prevents either GAP from dephos-
phorylating and inactivating their respective GTPase,
thus prolonging GTPase activity, cellular motility
and invasion. Western blot analysis of 20 µg pro-
tein isolated from HME and SUM149 IBC cells
demonstrated expression of p120 in both cell lines
grown under normal conditions (Figure 4(A)) [54].
The SUM149 cells expressed higher levels of p120,
but also expressed a 100 kDa protein. Similarly, the
SUM149 cell line expressed significantly higher levels
of p190 than the HME cells (Figure 4(B)). This re-
sult is consistent with observations made in sponta-
neous potentially aggressive murine mammary tumors
[133].
To explore the hypothesis that p120 and p190 may
interact in human IBC cells, we performed immuno-
precipitations of p190 followed by immunoblotting
for p120. We also performed the reciprocal immun-
oprecipitation using an antibody to p120 followed by
immunoblotting for p190. Protein lysates were harves-
ted from HME and SUM149 IBC cells serum/growth
factor-starved for 16 h and then either left unstim-
ulated or stimulated for 1 h with 10% fetal bovine
serum.
Surprisingly, immunoprecipitation of 500 µg of
protein using a p190 antibody followed by immun-
oblotting for p120 did not demonstrate the predicted
120 kDa band, but rather a band at 100 kDa (Figure
4(C)). The 100 kDa band was consistently expressed
in the HME cells, whether the cells were grown under
serum/growth factor-free conditions or serum stimu-
lated. In contrast, the 100 kDa band was strongly asso-
ciated with p190 in the SUM149 cells grown under
serum-free conditions. After 1 h serum stimulation,
p100 associated with p190 was almost undetectable.
Upon examination of the literature, we found that
p120 RasGAP can exist in two forms, Type I RasGAP,
which is found to be 120 kDa in size and an altern-
atively spliced 100 kDa Type II form [134–136]. Ex-
pression of the Type II 100 kDa form of RasGAP has
previously been thought to be restricted to placental
trophoblasts, choriocarcinoma cells and leukemic cells
[134–138]. This is the first report of this protein being
involved in human breast cancer cells.
Even more interesting was the identification of a
105 kDa protein in the serum stimulated SUM149 IBC
cells (Figure 4(D)). Expression of this protein was not
seen in the serum starved SUM149 and barely de-
tectable in serum starved or stimulated HME cells.
Since the 105 kDa protein was detected by an anti-
body raised against the middle and GAP domain of
rat p190 RhoGAP, these data suggests that this is new
RhoGAP. Again, a review of the literature yielded a
single paper describing a 105 kDa RasGAP associated
protein [137]. The authors of this paper, Ye et al. iden-
tified, but did not clone or sequence a novel 105 kDa
protein associated with p120 Type I and p100 Type II
RasGAP in human trophoblasts and choriocarcinoma
cells that were induced to differentiate with okadaic
acid [137].
Taken together, our data suggest that p105 and
p100 may be the GAPs involved in regulating RhoC
GTPase activity in RhoC overexpressing IBC cells.
We are currently cloning and characterizing p105 in
our IBC cells.
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Figure 4. Results of immunoprecipitations and western blot analysis of Rho and Ras GAPs in IBC cells. Panels A and B are western blots for
p120 RasGAP and p190 RhoGAP, respectively, in HME and SUM149 cells at 70% confluence grown under normal conditions. An antibody
specific for p120 RasGAP (Upstate Biotechnology cat. No. 5–178) was used to detect p120 in 20 µg protein. The p120 RasGAP was detected
in both the HME and SUM149 cells however an alternatively spliced form was detected at p100. Higher levels of p120 were detected in the
SUM149 IBC cells. Similarly, p190 RhoGAP was detected in both the HME and SUM149 cells using a monoclonal antibody directed to
the GAP domain of p190 (Upstate Biotechnology cat. No. 05–378). Higher levels of p190 were detected in the SUM149 IBC cells than the
HME cells. β-actin was used as a loading control. The interaction between p120 and p190 was analyzed in HME and SUM149 cells grown
under serum/growth factor-free (SFM) conditions or serum (10% MEM) stimulated for 1 h. Panel C is the result of an immunoprecipitation
using the p190 antibody followed by immunoblotting with the p120 antibody. No p120 was detected in either cell line regardless of growth
condition, rather the p100 form of RasGAP was detected. The levels of p100 were slightly higher in the serum stimulated HME cells than
those grown in SFM. Levels of p100 were high in the SUM149 cells grown in SFM but disappeared after serum stimulation. In the reciprocal
immunoprecipitation using a p120 antibody followed by immunoblotting with a p190 antibody (Panel D), p190 was detected in the SUM149
serum stimulated cells. More interestingly, a strong band was detected at p105 in the SUM149 serum stimulated cells.
Challenges for the future
Interest in Rho GTPase expression, as it pertains to the
progression of breast and other cancers, has increased
dramatically over the past half decade. Elucidating
the mechanisms that result in Rho-overexpression and
activation are key in understanding the role of these
proteins in breast cancer progression and metastasis. It
is apparent that a delicate equipoise between the Rho-
regulatory proteins exists. This fine balance keeps the
Rho GTPases in equilibrium between an inactive and
active state. Plainly, perturbation of any of the Rho-
regulatory proteins, either through mutation, growth
factor receptor dysregulation or oncogene expression
can lead to aberrant Rho activation, increased motil-
ity, invasion and possibly metastasis. With the large
number of RhoGDIs, RhoGEFs and RhoGAPs thus
far identified, and more being continuously added to
the list, the main challenge will be to find the key
molecules involved in Rho-dysregulation.
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